-
81.发明申请METHODS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS 有权用内皮素，内皮素激动剂和ADRENOMEDULLIN ANTAGONISTS诊断和治疗关键病人的方法公开(公告)号：US20100209433A1
公开(公告)日：2010-08-19
申请号：US12095675
申请日：2005-12-01
IPC分类号： A61K39/395 , A61K38/17 , A61P35/00 , A61P29/00 , A61P9/00 , A61P7/00 , A61P31/00 , A61P1/18 , G01N33/53
CPC分类号： G01N33/74 , A61K39/3955 , C07K16/26
摘要： The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.Submitted herewith is a sequence listing in computer readable form for entry into the present application. Also enclosed is a pdf copy of the as-filed sequence listing and a Checker Program report indicating that the text file of the sequence listing contains no errors.
摘要翻译： 危重病人体液中前肾上腺髓质素（pro-adrenomedullin（pro-ADM）/ pro-endothelin（pro-end））免疫反应性的比例用于诊断，病程控制和预后，包括对死亡风险的评估 严重的威胁生命的疾病。 此外，提供了治疗具有高水平的pro-ADM但具有包含血管收缩性内皮素或其前体的药物和/或内皮素激动剂或肾上腺髓质素拮抗剂的前-THT免疫反应性水平不足的危重患者。 本文提供的是用于输入本申请的计算机可读形式的序列表。 还附有所提交的序列表的pdf副本以及指示序列表的文本文件不包含错误的检查程序报告。
-
82.发明授权Method for diagnosis of alzheimer's disease with determination of LASP-1 immunoreactivity 失效用于确定LASP-1免疫反应性的阿尔茨海默病的诊断方法公开(公告)号：US07763435B2
公开(公告)日：2010-07-27
申请号：US12041370
申请日：2008-03-03
IPC分类号： G01N33/53
CPC分类号： G01N33/566 , G01N33/6893 , G01N33/6896 , G01N2800/26
摘要： Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
摘要翻译： 用于早期诊断和诊断的方法，用于预测和评估炎性疾病和感染，特别是脓毒症样全身感染和阿尔茨海默氏病的严重性和治疗伴随监测，其中蛋白质LASP- 1（SEQ ID NO：1）或蛋白质LAP-1（SEQ ID NO：16）或这些蛋白质之一的游离和/或蛋白结合形式的免疫反应性片段优选作为免疫反应性 生物流体或任选的组织样品，并且根据存在和/或数量的炎症性疾病或感染的治疗的存在，预期进程，严重程度或成功性得出结论 的蛋白质。
-
83.发明申请DIAGNOSIS AND RISK CLASSIFICATION OF ACUTE CORONARY SYNDROME BY MEANS OF CT-PROET-1 IN COMBINATION WITH NT-PROBNP 有权通过CT-PROET-1与NT-PROBNP组合的诊断和风险分类冠状动脉综合征公开(公告)号：US20100151504A1
公开(公告)日：2010-06-17
申请号：US12520166
申请日：2007-12-22
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2800/324
摘要： The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.
摘要翻译： 本发明涉及用于急性冠状动脉综合征（ACS）的诊断和/或风险分类的方法，特别是用于急性心肌梗塞（AMI）和心绞痛（AP）和/或心肌梗塞后的方法，其中确定 C-末端内皮素（CT-proET-1）或其片段和部分肽与NT-proBNP组合进行。
-
84.发明申请公开(公告)号：US20100035275A1
公开(公告)日：2010-02-11
申请号：US12514194
申请日：2007-11-08
CPC分类号： G01N33/6893 , G01N33/74 , G01N2800/042
摘要： The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.
摘要翻译： 本发明涉及一种用于胰腺糖尿病，特别是糖尿病后遗症的诊断和/或风险评估的方法，其中确定标记中间区域肾上腺髓质素（MR-proADM：SEQ ID No.2）或部分肽或片段 或者如果包含在标记组合（面板，群集）中，则对被调查的患者进行。 本发明还涉及用于执行所述方法的诊断装置和套件。
-
公开(公告)号：US20090311719A1
公开(公告)日：2009-12-17
申请号：US12091261
申请日：2006-10-26
申请人： Andreas Bergmann , Joachim Struck , Andrea Ernst
发明人： Andreas Bergmann , Joachim Struck , Andrea Ernst
IPC分类号： C12Q1/25
CPC分类号： G01N33/6896 , C12Q1/34 , C12Q1/48
摘要： Disclosed is an in vitro method for the detection, for the determination of the severity and for the assessment of the progress and prediction of neurodegenerative diseases, in which the presence and/or concentration of carbamoyl phosphate synthetase 1 (CPS 1) is determined in a biological fluid of a patient who suffers from a neurodegenerative disease or is suspected of suffering from such a disease, and conclusions about the presence, progression, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the determined presence and/or concentration of CPS 1 or the non-detectability of a CPS 1 immune reactivity.
摘要翻译： 公开了一种体外检测方法，用于确定严重程度和评估神经变性疾病的进展和预测，其中氨基甲酰磷酸合成酶1（CPS 1）的存在和/或浓度在 患有神经变性疾病或怀疑患有这种疾病的患者的生物流体，并且基于所确定的存在和/或结果，绘制关于神经变性疾病的治疗的存在，进展，严重性或成功的结论， 或CPS 1的浓度或CPS1免疫反应性的不可检测性。
-
86.发明申请公开(公告)号：US20090176267A1
公开(公告)日：2009-07-09
申请号：US12299829
申请日：2007-05-08
IPC分类号： C12Q1/02
CPC分类号： G01N33/6893 , G01N2800/085
摘要： Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.
摘要翻译： 公开了一种用于鉴定和伴随监测药物诱导或成瘾物质诱导的肝损伤的治疗和治疗的体外方法，其中确定人酶氨基甲酰合酶1（CPS 1）或其浓度的发生 来自患有或已经被潜在的肝损伤药物治疗的患者的血清或血浆样品，或者来自服用有害兴奋剂和成瘾物质或暴露于肝毒性物质的人。
-
公开(公告)号：US07498139B2
公开(公告)日：2009-03-03
申请号：US10808368
申请日：2004-03-25
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/74 , C07K14/585 , G01N2333/585
摘要： Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
摘要翻译： 用于诊断和治疗败血症疾病的重组降钙素原3-116的用途和除降钙素原以外的促激素以及二肽基肽酶IV的测定作为诊断败血症的生物标志物。
-
88.发明申请USES OF CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS 1) AND IT'S FRAGMENTS FOR THE DIAGNOSIS OF LIVER DISEASES 审中-公开碳水化合物合成酶1（CPS 1）的使用及其对肝脏疾病诊断的片段公开(公告)号：US20080176259A1
公开(公告)日：2008-07-24
申请号：US12040375
申请日：2008-02-29
申请人： Andreas Bergmann , Joachim Struck , Monika Uhlein
发明人： Andreas Bergmann , Joachim Struck , Monika Uhlein
CPC分类号： G01N33/6893 , C12Q1/34 , C12Q1/48 , G01N2333/9015 , G01N2800/26
摘要： Use of carbamoyl phosphate synthetase 1 (CPS 1) and/or of fragments of the N-terminal part of CPS 1 from body fluids or body tissues as marker peptides for the diagnosis and for the prognosis and the monitoring of inflammations and infections, including sepsis, and of liver failure as part of multiorgan failure or for determinations in connection with inflammatory and other liver diseases.
摘要翻译： 使用氨基甲酰磷酸合成酶1（CPS 1）和/或CPS 1的N末端部分片段从体液或身体组织中作为标志物肽用于诊断和预后以及监测炎症和感染，包括败血症 ，以及作为多器官衰竭或与炎性和其他肝脏疾病有关的确定的一部分的肝衰竭。
-
公开(公告)号：US20060234295A1
公开(公告)日：2006-10-19
申请号：US10535875
申请日：2003-10-16
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
CPC分类号： G01N33/76 , G01N33/6893 , G01N2333/58
摘要： Disclosed is an improved sandwich immunoassay for identifying partial proANP peptides in cardiac and sepsis diagnosis by using two antibodies which specifically bond to partial sequences in the mid-regional area of NT-proANP, extending from amino acid 53 to amino acid 83 of NT-proANP.
摘要翻译： 公开了通过使用特异性结合NT-proANP的中间区域的部分序列的两种抗体来鉴定心脏和败血症诊断中的部分proANP肽的改进的夹心免疫测定，其从氨基酸53延伸到NT-proANP的氨基酸83 。
-
90.发明授权Receptor binding assays and reagent kit for detecting TSH receptor autoantibodies 有权用于检测TSH受体自身抗体的受体结合测定和试剂盒公开(公告)号：US07015003B1
公开(公告)日：2006-03-21
申请号：US09381032
申请日：1999-01-13
申请人： Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Wolfgang Weglöhner , Jörg-Michael Hollidt
发明人： Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Wolfgang Weglöhner , Jörg-Michael Hollidt
IPC分类号： G01N33/53 , G01N33/537 , G01N33/557 , G01N33/542
CPC分类号： G01N33/564 , G01N33/76
摘要： Improved receptor assays for the detection of thyroid stimulating hormone receptor (TSHR) autoantibodies are described which use immobilized, affinity-purified rTSHR preparations as specific binders. This format, as well as novel measures for neutralizing pathologically increased human TSH (hTSH) levels in the sera, e.g., by the addition of anti-hHSH antibody, and/or eliminating the influence of anti-bovine TSH antibody, result in increased assay reliability and open up the possibility of preparing the assay constituents in a ready to use and/or well-standardized form for automatic processing and/or convenient marketing.
摘要翻译： 描述了用于检测甲状腺刺激激素受体（TSHR）自身抗体的改进的受体测定法，其使用固定化的亲和纯化的rTSHR制剂作为特异性结合剂。 这种形式，以及用于中和病毒性增加血清中的人TSH（hTSH）水平的新措施，例如通过加入抗hHSH抗体和/或消除抗牛TSH抗体的影响导致增加的测定 并开放了准备使用和/或标准化的形式进行自动处理和/或方便营销的测定成分的可能性。
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.03 秒)
